Inferra AIResearch Tools

Inferra AI / Company / TECH

Bio-Techne

TECH · Health Care

Last earnings Aug 12, 2026

Key results

Revenuequarter

3%

Fourth Quarter FY2025 Highlights Fourth quarter organic revenue increased by 3% (4% reported) to $317.0 million.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Revenuefull-year

5%

Full year organic revenue increased 5% (5% reported) to $1.2 billion.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

EPSfull-year

$0.25

GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Net revenuequarter

4%

Fourth Quarter Fiscal 2025 Revenue Net sales for the fourth quarter increased 4% to $317.0 million.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Organic revenuequarter

3%

Organic revenue increased 3% compared to the prior year.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Foreign currency exchange had a favorable impact of 2%, and non-recurring prior year revenue from a business held-for-sale had an unfavorable impact of 1%.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

GAAP operating incomequarter

152%

GAAP operating income for the fourth quarter of fiscal 2025 decreased 152% to ($23.9) million, compared to $45.8 million in the fourth quarter of fiscal 2024.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Adjusted operating incomequarter

$101.3 million

Adjusted operating income of $101.3 million in the fourth quarter of fiscal 2025 remained relatively consistent with fourth quarter of fiscal 2024 adjusted operating income of $101.8 million.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

AI analysis

Q4 FY2025 · reported Aug 6, 2025

Based on: Earnings release + parent 8-K — transcript not held

EPS · Q4 FY2025
$0.25
EX-99 · Aug 6, 2025
Adjusted operating income · Q4 FY2025
$101.3M
EX-99 · Aug 6, 2025

Headline figures

MetricQ4 FY2025Prior qtrYear ago
Revenue3%——
Net revenue4%——
Organic revenue3%——
GAAP operating income152%——
Adjusted operating income$101.3 million——

EX-99 · Aug 6, 2025

Guidance · company-stated

No guidance located in the held release

Next earningsNo verified date on fileNo date is estimated or imported

Company-stated claims

Aug 12, 2026

Historical · increased 146% · income

“GAAP operating income for full year fiscal 2026 increased 146% to $251.9 million, compared to $102.3 million in the full year fiscal 2025.”

EX-99 · Aug 12, 2026
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

GAAP earnings per share (EPS) was $ (0.11) versus $0.25 one year ago

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

No guidance located in the held release

Strategy & priorities

Announced divestiture of the Exosome Diagnostics business including the ExoDx Prostate test (EPI) as the Company emphasizes investment and commercial priorities on non-CLIA based product lines in their growth pillars.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

This strategic decision will immediately strengthen our profitability and allow us to increase our focus on high-growth areas, particularly tools for research and precision diagnostics.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

The segment s operating margin increased primarily due to favorable volume leverage and ongoing profitability initiatives.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Risks & headwinds

Bio-Techne delivered a solid fourth quarter that was in-line with our expectations, despite ongoing market uncertainty, said Kim Kelderman, President and Chief Executive Officer of Bio-Techne.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Kelderman concluded, While market uncertainties persist, I have full confidence in our team s ability to navigate the evolving landscape and continue delivering meaningful value to all our stakeholders.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses).

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Such statements involve risks and uncertainties that may affect the actual results of operations.

SEC original ↗Bio-Techne — Earnings release (8-K exhibit)EX-99Aug 6, 2025

Documents

Earnings deck slides

0 decks with slide view

Bio-Techne — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Named in the company’s own filings

People Inc (PPLI)“Develop People Through a Transformative Culture.”

Filings

40 documents

Earnings releases

12 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Bio-Techne are held in this edition of the library.

Mentioned by

8 companies

Other tracked companies whose held documents mention Bio-Techne by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.